Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
294,683,714
-
Total 13F shares
-
102,140,618
-
Share change
-
-3,463,588
-
Total reported value
-
$61,237,233
-
Put/Call ratio
-
123%
-
Price per share
-
$0.60
-
Number of holders
-
129
-
Value change
-
-$4,209,968
-
Number of buys
-
41
-
Number of sells
-
72
Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q3 2023
As of 30 Sep 2023,
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) was held by
129 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
102,140,618 shares.
The largest 10 holders included
WASATCH ADVISORS LP, BlackRock Inc., VANGUARD GROUP INC, Rokos Capital Management LLP, CITADEL ADVISORS LLC, CREDIT SUISSE AG/, GEODE CAPITAL MANAGEMENT, LLC, ACADIAN ASSET MANAGEMENT LLC, STATE STREET CORP, and D. E. Shaw & Co., Inc..
This page lists
130
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.